Meeting
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
Authors
Theodore Willis Laetsch
Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA
Theodore Willis Laetsch , Katherine A. Janeway , Douglas S. Hawkins , Katarzyna Juszczak-Kosela , Jodi Ann Muscal , Anderson B. Collier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT03709680
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11583)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11583
Abstract #
TPS11583
Poster Bd #
486b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.
First Author: Gertjan VAN HAL
Poster
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
First Author: Theodore Willis Laetsch
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster